Five Prime Therapeutics — ASCO 2018
15 slides from Five Prime Therapeutics's conference presentation, Jun 4, 2018
Slide 1: Pharmacodynamics and Genomic Profiling of Patients Treated With Cabiralizumab + Nivolumab
Pharmacodynamics and Genomic Profiling of Patients Treated With Cabiralizumab + Nivolumab Provide Evidence of On-Target Tumor Immune Modulations and Support Future Clinical Applications Michael Carleton,1 Janine Powers,2 Penny Phillips,1 Muhammad Beg,3 James Lee,4 Osama Rahma,5 Sarina A. Piha-Paul,6
Slide 2: Background
Background Immune checkpoint blockade with anti‒PD-1 therapies has demonstrated durable clinical benefit in patients with advanced malignancies1; however, antitumor responses are often dampened by an immunosuppressive tumor microenvironment (TME)2 Inhibiting signaling pathways that stimulate the dev
Slide 3: Background: CSF-1R pathway and cabiralizumab rationale
Background The colony-stimulating factor 1 receptor (CSF-1R) pathway promotes macrophage differentiation, proliferation, and survival. 2,3,7,8 In the TME, this leads to development, maintenance, and function of immunosuppressive TAMs 2,3,7 Cabiralizumab is a humanized IgG4 monoclonal antibody that b
Slide 4: Background: Phase 1a/1b study of cabiralizumab with nivolumab
Background Initial results from a phase 1a/1b study of cabiralizumab in combination with nivolumab (anti‒PD-1) in patients with advanced solid tumors (NCT02526017; Figure 2) showed that the combination was tolerable, with preliminary evidence of durable clinical benefit in heavily pretreated patient
Slide 5: Methods
Methods TMB was measured by whole exome sequencing of archival or fresh biopsy samples from patients treated during dose expansion Changes in peripheral concentrations of CSF-1R ligands (CSF-1 and IL-34) were measured by enzyme-linked immunosorbent assay (ELISA), and changes in nonclassical monocyte
Slide 6: Baseline TMB levels in patients treated during dose expansion
Figure 3. Baseline TMB levels in patients treated during dose expansion Results aArrow denotes 199 missense mutations by WES equivalent to the F1CDx cutoff value of 10 mut/Mb used in CheckMate-02611 CM = CheckMate; F1CDx = FoundationOne CDx; Mb = megabase; mut = mutations; NSCLCn = NSCLC (PD-1 naive
Slide 7: Dose-dependent changes in peripheral CSF-1 and nonclassical monocytes
Figure 4. Dose-dependent changes in peripheral CSF-1 and nonclassical monocytes were observed with cabiralizumab ≥ 4 mg/kg + nivolumab Results Peripheral pharmacodynamic changes Consistent changes in the levels of circulating CSF-1 and nonclassical monocytes following treatment were dose dependent (
Slide 8: Schedule-dependent changes in peripheral CSF-1 and nonclassical monocytes
Figure 5. Schedule-dependent changes in peripheral CSF-1 and nonclassical monocytes showed optimal kinetics with the Q2W regimen Results Peripheral pharmacodynamic changes Changes in the levels of circulating CSF-1 and nonclassical monocytes following treatment were schedule dependent (Figure 5) CSF
Slide 9: CSF-1R and M2 macrophages decreased in tumors
Figure 6. CSF-1R and M2 macrophages decreased in tumors of patients treated with cabiralizumab + nivolumab Results Tumor pharmacodynamic changes aIncreases > 200% from baseline were observed for CSF-1R (n = 5), CD163 (n = 7), and CD68 (n = 6) Change in expression of CSF-1R and macrophage markers (da
Slide 10: CSF-1R+ macrophages decreased in the tumors of patients + nivolumab
Figure 7. CSF-1R+ macrophages decreased in the tumors of patients treated with cabiralizumab + nivolumab Results Tumor pharmacodynamic changes CSF-1R+ macrophages decreased in patients treated with the combination (Figure 7) Baseline and on-treatment biopsy samples from patients with ovarian and pan
Slide 11: CD8+ effector T cells increased in tumors of patients + nivolumab
Figure 8. CD8+ effector T cells increased in tumors of patients treated with cabiralizumab + nivolumab Results Tumor pharmacodynamic changes Change in expression of CD8+ effector T cells (day 28) Median change from baseline, % Patients with increase from baseline, % +38 (P = 0.029) 58 CD8+ effector
Slide 12: Expression of CSF-1R ligands and pro-inflammatory genes increased in responders
Figure 9. Expression of CSF-1R ligands and pro-inflammatory genes increased in tumors of responders but not in nonresponders Results Gene expression profiling Significant increases in the expression of CSF-1R ligands and pro-inflammatory markers were observed in patients who responded to treatment w
Slide 13: Gene expression profiling: CD8+ T-cell genes in responders
Results Gene expression profiling Significant increases in the expression of genes associated with CD8+ T cells and CD8+ T-cell cytolytic and inhibitory receptor signatures were observed in patients who responded to the combination (Figure 10A) No significant changes were observed in nonresponders (
Slide 14: Conclusions
Conclusions Peripheral- and tumor-based analyses demonstrated cabiralizumab-mediated CSF-1R blockade in the periphery and TME in patients with advanced cancer treated with cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Q2W Circulating CSF-1 increased, and nonclassical monocytes decreased In tumors, CSF-1
Slide 15: References
References Sharma P, et al. Cell 2017;168:707–723. Zhu Y, et al. Cancer Res 2014;74:5057–5069. Chanmee T, et al. Cancers 2014;6:1570‒1690. Hu H, et al. Tumour Biol 2016;37:8657–8664. Kurahara H, et al. J Surg Res 2011;167:e211–e219. Yang L, Zhang Y. J Hematol Oncol 2017;10:58. Cannarile MA, et al. J